Literature DB >> 23529739

Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.

Maria Simitsopoulou1, Pavla Peshkova, Efthymia Tasina, Aspasia Katragkou, Daniela Kyrpitzi, Aristea Velegraki, Thomas J Walsh, Emmanuel Roilides.   

Abstract

Candida species other than Candida albicans are increasingly recognized as causes of biofilm-associated infections. This is a comprehensive study that compared the in vitro activities of all three echinocandins against biofilms formed by different common and infrequently identified Candida isolates. We determined the activities of anidulafungin (ANID), caspofungin (CAS), and micafungin (MFG) against planktonic cells and biofilms of bloodstream isolates of C. albicans (15 strains), Candida parapsilosis (6 strains), Candida lusitaniae (16 strains), Candida guilliermondii (5 strains), and Candida krusei (12 strains) by XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] assay. Planktonic and biofilm MICs were defined as ≥ 50% fungal damage. Planktonic cells of all Candida species were susceptible to the three echinocandins, with MICs of ≤ 1 mg/liter. By comparison, differences in the MIC profiles of biofilms in response to echinocandins existed among the Candida species. Thus, C. lusitaniae and C. guilliermondii biofilms were highly recalcitrant to all echinocandins, with MICs of ≥ 32 mg/liter. In contrast, the MICs of all three echinocandins for C. albicans and C. krusei biofilms were relatively low (MICs ≤ 1 mg/liter). While echinocandins exhibited generally high MICs against C. parapsilosis biofilms, MFG exhibited the lowest MICs against these isolates (4 mg/liter). A paradoxical growth effect was observed with CAS concentrations ranging from 8 to 64 mg/liter against C. albicans and C. parapsilosis biofilms but not against C. krusei, C. lusitaniae, or C. guilliermondii. While non-albicans Candida planktonic cells were susceptible to all echinocandins, there were drug- and species-specific differences in susceptibility among biofilms of the various Candida species, with C. lusitaniae and C. guilliermondii exhibiting profiles of high MICs of the three echinocandins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529739      PMCID: PMC3716187          DOI: 10.1128/AAC.02541-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  61 in total

1.  Biofilm formation by five species of Candida on three clinical materials.

Authors:  D Estivill; A Arias; A Torres-Lana; A J Carrillo-Muñoz; M P Arévalo
Journal:  J Microbiol Methods       Date:  2011-06-12       Impact factor: 2.363

2.  Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum.

Authors:  Ryan K Shields; M Hong Nguyen; Chen Du; Ellen Press; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 3.  Candida species: new insights into biofilm formation.

Authors:  Mayra Cuéllar-Cruz; Everardo López-Romero; Julio C Villagómez-Castro; Estela Ruiz-Baca
Journal:  Future Microbiol       Date:  2012-06       Impact factor: 3.165

4.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

5.  Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.

Authors:  Marlene Axner-Elings; Silvia Botero-Kleiven; Rasmus Hare Jensen; Maiken Cavling Arendrup
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

6.  Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis.

Authors:  Ali Abdul Lattif; Pranab K Mukherjee; Jyotsna Chandra; Kim Swindell; Shawn R Lockhart; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum
Journal:  Int J Med Microbiol       Date:  2009-11-22       Impact factor: 3.473

7.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.

Authors:  William J Steinbach; Emmanuel Roilides; David Berman; Jill A Hoffman; Andreas H Groll; Ibrahim Bin-Hussain; Debra L Palazzi; Elio Castagnola; Natasha Halasa; Aristea Velegraki; Christopher C Dvorak; Arunaloke Charkabarti; Lillian Sung; Lara Danziger-Isakov; Catherine Lachenauer; Antonio Arrieta; Katherine Knapp; Mark J Abzug; Christine Ziebold; Thomas Lehrnbecher; Lena Klingspor; Adilia Warris; Kateri Leckerman; Teresa Martling; Thomas J Walsh; Daniel K Benjamin; Theoklis E Zaoutis
Journal:  Pediatr Infect Dis J       Date:  2012-12       Impact factor: 2.129

9.  Elevated chitin content reduces the susceptibility of Candida species to caspofungin.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

10.  Candida biofilms and the host: models and new concepts for eradication.

Authors:  Hélène Tournu; Patrick Van Dijck
Journal:  Int J Microbiol       Date:  2011-11-14
View more
  17 in total

1.  Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms.

Authors:  M Guembe; J Guinea; L J Marcos-Zambrano; A Fernández-Cruz; T Peláez; P Muñoz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 2.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 3.  Mechanisms of echinocandin antifungal drug resistance.

Authors:  David S Perlin
Journal:  Ann N Y Acad Sci       Date:  2015-07-17       Impact factor: 5.691

4.  Caspofungin at catheter lock concentrations eradicates mature biofilms of Candida lusitaniae and Candida guilliermondii.

Authors:  Maria Simitsopoulou; Daniela Kyrpitzi; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

Review 5.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

6.  In vitro activity of micafungin against biofilms of Candida albicans, Candida glabrata, and Candida parapsilosis at different stages of maturation.

Authors:  Małgorzata Prażyńska; Tomasz Bogiel; Eugenia Gospodarek-Komkowska
Journal:  Folia Microbiol (Praha)       Date:  2017-10-05       Impact factor: 2.099

7.  Pharmacodynamic and Immunomodulatory Effects of Micafungin on Host Responses against Biofilms of Candida parapsilosis in Comparison to Those of Candida albicans.

Authors:  Maria Simitsopoulou; Katerina Chlichlia; Daniela Kyrpitzi; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

8.  Lack of efficacy of echinocandins against high metabolic activity biofilms of Candida parapsilosis clinical isolates.

Authors:  Danilo Yamamoto Thomaz; Marcia de Souza Carvalho Melhem; João Nobrega de Almeida Júnior; Gil Benard; Gilda Maria Barbaro Del Negro
Journal:  Braz J Microbiol       Date:  2020-01-02       Impact factor: 2.476

Review 9.  Mechanisms of Candida Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics.

Authors:  Konstantin A Demin; Aleksandr G Refeld; Anna A Bogdanova; Evgenya V Prazdnova; Igor V Popov; Olga Yu Kutsevalova; Alexey M Ermakov; Anzhelica B Bren; Dmitry V Rudoy; Vladimir A Chistyakov; Richard Weeks; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-18       Impact factor: 4.609

Review 10.  Micafungin: an evidence-based review of its place in therapy.

Authors:  Pola de la Torre; Annette C Reboli
Journal:  Core Evid       Date:  2014-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.